Plunkett Research Online: Mesoblast Limited

MESOBLAST LIMITED (MESO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Mesoblast Limited is an Australian biotechnology company engaged in the development of innovative cellular medicines. The company’s proprietary technology platform is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs) to establish a broad portfolio of late-stage product.....



Mesoblast Limited
Ticker: MESO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 613 96396036
Fax: 613 96396030
Address: Level 38, 55 Collins Street
Melbourne, VIC 3000 Australia

Types Of Business
Industry Ranks

Industry NAICS code:

Research and Development in Biotechnology
ContactsDescription
Silviu ItescuCEO/Director
Joshua MuntnerCFO
See More
Mesoblast Limited is an Australian biotechnology company engaged in the development of innovative cellular medicines. The company’s proprietary technology platform is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs) to establish a broad portfolio of late-stage product.....See More See More

Auditor: PricewaterhouseCoopers
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201820172016201520142013
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
TEMCELL
NameTitleSalary (AUD)Bonus (AUD)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: